Neelam

Fractal adds two prominent tech executives to its board

Retrieved on: 
Tuesday, February 21, 2023

NEW YORK, Feb. 21, 2023 /PRNewswire/ -- Fractal (fractal.ai), a global provider of artificial intelligence and advanced analytics to Fortune® 500 companies, today announced the appointment of Karenann Terrell and Neelam Dhawan as independent directors to its board of directors.

Key Points: 
  • "I look forward to collaborating with the entire board and management team to help Fractal achieve its goals and deliver long-term value to all stakeholders."
  • "We are honored to welcome Karenann and Neelam – two accomplished tech leaders and role models to the Fractal board.
  • Neelam's rich experience, especially in the tech industry will be invaluable as we scale Fractal and navigate through several points of inflection over the next few years.
  • Their depth of industry knowledge and expertise are valuable additions to the board that will help Fractal continue its strong growth," said Pranay Agrawal, Co-founder & Chief Executive Officer, Fractal.

Fractal adds two prominent tech executives to its board

Retrieved on: 
Tuesday, February 21, 2023

NEW YORK, Feb. 21, 2023 /PRNewswire/ -- Fractal (fractal.ai), a global provider of artificial intelligence and advanced analytics to Fortune® 500 companies, today announced the appointment of Karenann Terrell and Neelam Dhawan as independent directors to its board of directors.

Key Points: 
  • "I look forward to collaborating with the entire board and management team to help Fractal achieve its goals and deliver long-term value to all stakeholders."
  • "We are honored to welcome Karenann and Neelam – two accomplished tech leaders and role models to the Fractal board.
  • Neelam's rich experience, especially in the tech industry will be invaluable as we scale Fractal and navigate through several points of inflection over the next few years.
  • Their depth of industry knowledge and expertise are valuable additions to the board that will help Fractal continue its strong growth," said Pranay Agrawal, Co-founder & Chief Executive Officer, Fractal.

Agenus Advances Portfolio with 6 Clinical Collaborations

Retrieved on: 
Tuesday, May 31, 2022

These 6 collaborations span a range of Agenus clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON.

Key Points: 
  • These 6 collaborations span a range of Agenus clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON.
  • The combination studies are being sponsored and executed by our collaborators, with drug supply and scientific support provided by Agenus.
  • This strategy, enabled by in-house integrated manufacturing and scientific capabilities, positions Agenus to achieve the insights and advances needed to drive development on accelerated timelines.
  • Agenus new and ongoing clinical collaborations are supporting and enabling:
    Targovax to conduct a clinical trial combining botensilimab and balstilimab with ONCOS-102 (oncolytic virus) in patients with PD-1 relapsed/refractory melanoma.

Neelam Sharma Joins K2 Integrity as Global Head of Business Development and Sales

Retrieved on: 
Thursday, December 9, 2021

NEW YORK, Dec. 9, 2021 /PRNewswire/ -- K2 Integrity today announced Neelam Sharma has joined the firm as Global Head of Business Development and Sales.

Key Points: 
  • NEW YORK, Dec. 9, 2021 /PRNewswire/ -- K2 Integrity today announced Neelam Sharma has joined the firm as Global Head of Business Development and Sales.
  • As part of the firm's global leadership team, Ms. Sharma will be responsible for creating and shaping K2 Integrity's suite of products and services to deliver cutting-edge digital solutions for the firm's growing global client base.
  • "When it comes to understanding the unique needs of our client base, Neelam's vision is second to none," said Andrew Rabinowitz , Co-CEO, K2 Integrity.
  • To learn more about how K2 Integrity is revolutionizing the management of risk, visit www.k2integrity.com , or follow us on Twitter or LinkedIn .

Neelam Sharma Joins K2 Integrity as Global Head of Business Development and Sales

Retrieved on: 
Thursday, December 9, 2021

NEW YORK, Dec. 9, 2021 /PRNewswire/ -- K2 Integrity today announced Neelam Sharma has joined the firm as Global Head of Business Development and Sales. As part of the firm's global leadership team, Ms. Sharma will be responsible for creating and shaping K2 Integrity's suite of products and services to deliver cutting-edge digital solutions for the firm's growing global client base.

Key Points: 
  • NEW YORK, Dec. 9, 2021 /PRNewswire/ -- K2 Integrity today announced Neelam Sharma has joined the firm as Global Head of Business Development and Sales.
  • As part of the firm's global leadership team, Ms. Sharma will be responsible for creating and shaping K2 Integrity's suite of products and services to deliver cutting-edge digital solutions for the firm's growing global client base.
  • "When it comes to understanding the unique needs of our client base, Neelam's vision is second to none," said Andrew Rabinowitz , Co-CEO, K2 Integrity.
  • To learn more about how K2 Integrity is revolutionizing the management of risk, visit www.k2integrity.com , or follow us on Twitter or LinkedIn .

Agenus Corporate Update and Third Quarter 2021 Financial Report

Retrieved on: 
Tuesday, November 9, 2021

With more than 100 patients treated with our Fc-enhanced CTLA-4 antibody, AGEN1181, we are very encouraged by the clinical responses achieved across tumor types.

Key Points: 
  • With more than 100 patients treated with our Fc-enhanced CTLA-4 antibody, AGEN1181, we are very encouraged by the clinical responses achieved across tumor types.
  • Of note, we are seeing responses in patients who have failed to respond to all other treatment, including PD-1 inhibitors, said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus.
  • We have also successfully completed an initial public offering for MiNK Therapeutics, and have launched our adjuvant business, SaponiQx.
  • Non-cash operating expenses for the nine-months ended September 30, 2021 were $46 million compared to $35 million for the same period of 2020.